Daily treatment with standard-dose aciclovir delays HIV disease progression and lowers viral load in patients co-infected with herpes simplex virus-2 (HSV-2), results of a study presented to the Sixth International AIDS Conference in Rome show.
Join the KC team
Do you want to become a Key Correspondent? Find out how >Related articles
Sign-up for emails

